A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-09-12
Adverse events
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-10-02 (study day 5); relationship: not assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-11 (study day 14); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 21); relationship: not assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-11-10 (study day 44); relationship: not assessed
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-07 (study day 71); relationship: Y
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-15 (study day 79); relationship: not assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-06 (study day 101); relationship: not assessed
Grade 2 Alopecia — outcome: UNKNOWN; onset 2023-02-21 (study day 147); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 151); relationship: not assessed
Data queries
No data queries.